UVA Health System, Department of Pediatrics seeks: children and adolescents with intermediate-risk neuroblastoma who are 12 years old or less at the time of initial diagnosis for research study.

The overall goal of the study is to determine if patients with intermediate-risk neuroblastoma can receive less chemotherapy than previously thought possible, without lowering the chance of survival. Other goals of this study are to: (a) treat all patients with recurrent, localized intermediate-risk neuroblastoma with a consistent chemotherapy plan and determine how many patients will survive without any further problem with their neuroblastoma, and to (b) do special studies on the blood, bone marrow and tumor tissue to determine if scientists can discover any new markers or features of intermediate-risk neuroblastoma that will some day help doctors understand which patients can safely receive less chemotherapy, and which patients may need more chemotherapy, to get rid their tumors for as long as possible.

The study involves blood draws, physical exams, urinalysis, test for kidney function, test for thyroid function, test for heart function (echocardiogram), spine X-ray, CT/MRI scans and taking FDA approved chemotherapy agents. Depending on the treatment plan you receive, the study may also involve surgery. The length of the visits will be comparable to the length of the visits you would receive for standard of care treatment. The number of visits you will have may be fewer than standard of care depending on which treatment you receive. Patients are expected to receive treatment on this study for 2-6 months. Data may be collected on patients for 10 years after the study closes to new patient enrollment.

You and/or your insurance will be billed for all study related medication, tests, treatment, and procedures.

Compensation

No compensation is provided for this study.